Impending Generic Competition Forces Innovation In Alzheimer's Treatments As the Baby Boomer generation reaches retirement age, the number of Americans suffering from Alzheimer's disease is expected to jump from 5 million to about 14 million in 2050.
Source: www.medicalnewstoday.comAmericans Show Little Tolerance For Mental Illness Despite Growing Belief In Genetic Cause A new study by University of Pennsylvania sociology professor Jason Schnittker shows that, while more Americans believe that mental illness has genetic causes, the nation is no more tolerant of the mentally ill than it was 10 years ago.
Source: www.medicalnewstoday.comSEROQUEL XR™ Improved Anxiety Symptoms By Day 4 In Generalised Anxiety Disorder - New Study Results Presented Today AstraZeneca announced new SEROQUEL XR™ (extended release quetiapine fumarate) clinical study data in patients with Generalised Anxiety Disorder (GAD), presented at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. In this study, extended release quetiapine fumarate significantly improved symptoms of anxiety at Week 8 compared with placebo and this was observed as early as day 4.
Source: www.medicalnewstoday.comWall Street Journal Examines Drugmakers' Use Of 'Unbranded Product Advertising' To Promote Disease Awareness, Treatment Options The Wall Street Journal on Friday examined "unbranded product advertising" for brand-name
drugs, which allow drugmakers to drive television viewers to Web sites promoting
drugs without the requirement of listing the products' side effects in the TV advertisement. FDA rules state that if an advertisement does not name a drug directly, it does not need to include a listing of possible side effects.
Source: www.medicalnewstoday.comCourt In Denmark Upholds Two Lipitor Patents, Prevents Launch Of Ranbaxy Generic Product Before November 2011 Pfizer Inc said that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company's favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed by Ranbaxy's generic atorvastatin product.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 PM
